|
|
|
| Clinical Efficacy of Intramuscular Injection of Sodium Dimercaptosulfonate and Oral Administration of Dimercaptosuccinic Acid Capsules in the Treatment of Patients with Chronic Arsenic Poisoning |
| YANG Yimei, HUANG Lei, WU Zhimin, et al |
| Hunan Prevention and Treatment Institute for Occupational Disease,Changsha Hunan 410007 |
|
|
|
|
Abstract 【Objective】 To explore the clinical efficacy of intramuscular injection of sodium dimercaptosulfonate and oral administration of dimercaptosuccinic acid capsules in the treatment of patients with chronic arsenic poisoning. 【Methods】 A retrospective analysis was conducted on the clinical data of 206 patients with chronic arsenic poisoning admitted to our hospital from January 2020 to December 2022. According to different treatment methods, they were divided into a control group (treated with dimercaptosuccinic acid) and an observation group (treated with intramuscular injection of sodium dimercaptosulfonate), with 103 patients in each group. The two groups of patients were treated continuously for 3 courses of treatment. We compared the clinical efficacy and arsenic concentration in hair and urine between two groups of patients before and after treatment.【Results】After treatment, the arsenic concentration in the hair and urine of the two groups of patients was significantly lower than before treatment, and the arsenic concentration in the hair and urine of the observation group was significantly lower than that of the control group, with statistical significance (P<0.05). The total effective rate of the observation group was 68.93% (71/103), significantly higher than the control group's 41.75% (43/103), and the difference was statistically significant (P<0.05). 【Conclusion】Early diagnosis and elimination of arsenic in the body are important measures in the treatment of chronic arsenic poisoning; Compared with dimercaptosuccinic acid, sodium dimercaptopropylsulfonate can significantly improve the overall effective rate of patients with chronic arsenic poisoning.
|
|
Received: 20 July 2023
|
|
|
|
|
|
[1] DEROSA C. Agency for Toxic Substances and Disease Registry's toxicological profiles: contribution to public health[J].Toxicol Ind Health,1994, 10(3): 117.
[2] 赖燕,肖雄斌,李海霞,等. 职业性慢性砷中毒周围神经病临床特征分析[J].实用预防医学, 2011, 18(6): 992-994.
[3] KUIVENHOVEN M, MASON K. Arsenic toxicity[J].Stat Pearls,2023, 3(8): 120-123.
[4] GROUP I W. Some drinking-water disinfectants and contaminants, including arsenic[J].IARC Monogr Eval Carcinog Risks Hum,2004, 84: 264-477.
[5] HAYAKAWA T, KOBAYASHI Y, CUI X, et al. A new metabolic pathway of arsenite: arsenic-glutathione complexes are substrates for human arsenic methyltransferase Cyt19[J].Arch Toxicol,2005, 79(4): 183-191.
[6] HUGHES M F, BECK B D, CHEN Y, et al. Arsenic exposure and toxicology: a historical perspective[J].Toxicol Sci,2011, 123(2): 305-332.
[7] RATNAIKE R N. Acute and chronic arsenic toxicity[J].Postgrad Med J,2003, 79(933): 391-396.
[8] OH S J. Electrophysiological profile in arsenic neuropathy[J].J Neurol Neurosurg Psychiatry,1991, 54(12): 1103-1105.
[9] MUKHERJEE S C, RAHMAN M M, CHOWDHURY U K, et al. Neuropathy in arsenic toxicity from groundwater arsenic contamination in West Bengal, India[J].J Environ Sci Health A Tox Hazard Subst Environ Eng,2003, 38(1): 165-183.
[10] MUCKE M, CUHLS H, RADBRUCH L, et al. Quantitative sensory testing (QST)[J].Schmerz,2021, 35(Suppl 3): 153-160.
[11] ROLDAN C J, ABDI S. Quantitative sensory testing in pain management[J].Pain Manag,2015, 5(6): 483-491.
[12] 尹厚民,冯蔚,丁美萍. 定量温度觉阈值对2型糖尿病患者的小纤维性感觉神经病变诊断的研究[J].中国应用生理学杂志, 2015, 31(2): 150-153.
[13] LAURIA G, MERKIES I S, FABER C G. Small fibre neuropathy[J].Curr Opin Neurol,2012, 25(5): 542-549.
[14] KROIGARD T, SOTHYNATHAN I, SINDRUP S H. Intraindividual variability and long-term changes of thermal quantitative sensory testing[J].J Clin Neurophysiol,2015, 32(4): 352-356. |
|
|
|
2023, Vol. 40 
